Tasly Pharmaceutical Group Co Ltd (600535) - Total Liabilities
Based on the latest financial reports, Tasly Pharmaceutical Group Co Ltd (600535) has total liabilities worth CN¥2.79 Billion CNY (≈ $407.97 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Tasly Pharmaceutical Group Co Ltd - Total Liabilities Trend (1999–2025)
This chart illustrates how Tasly Pharmaceutical Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Tasly Pharmaceutical Group Co Ltd (600535) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Tasly Pharmaceutical Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Tasly Pharmaceutical Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TechCreate Group Ltd.
NYSE MKT:TCGL
|
USA | $1.11 Million |
|
TOTVS S.A
SA:TOTS3
|
Brazil | R$7.75 Billion |
|
Green Brick Partners Inc
NYSE:GRBK
|
USA | $542.50 Million |
|
Sigma Advanced Systems Limited
NSE:MEGASOFT
|
India | Rs242.03 Million |
|
Wingtech Technology Co Ltd
SHG:600745
|
China | CN¥16.09 Billion |
|
Sany Heavy Equipment International Holdings Company Limited
F:YXS
|
Germany | €31.75 Billion |
|
Chemours Co
NYSE:CC
|
USA | $7.27 Billion |
|
Aneka Tambang (Persero) TBK (PT)
AU:ATM
|
Australia | AU$22.96 Trillion |
Liability Composition Analysis (1999–2025)
This chart breaks down Tasly Pharmaceutical Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 600535 stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.72 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tasly Pharmaceutical Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tasly Pharmaceutical Group Co Ltd (1999–2025)
The table below shows the annual total liabilities of Tasly Pharmaceutical Group Co Ltd from 1999 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥2.79 Billion ≈ $408.56 Million |
-2.55% |
| 2024-12-31 | CN¥2.87 Billion ≈ $419.25 Million |
-28.80% |
| 2023-12-31 | CN¥4.02 Billion ≈ $588.88 Million |
+5.92% |
| 2022-12-31 | CN¥3.80 Billion ≈ $555.97 Million |
+17.71% |
| 2021-12-31 | CN¥3.23 Billion ≈ $472.33 Million |
-21.45% |
| 2020-12-31 | CN¥4.11 Billion ≈ $601.34 Million |
-66.18% |
| 2019-12-31 | CN¥12.15 Billion ≈ $1.78 Billion |
-12.99% |
| 2018-12-31 | CN¥13.96 Billion ≈ $2.04 Billion |
+11.20% |
| 2017-12-31 | CN¥12.56 Billion ≈ $1.84 Billion |
+40.78% |
| 2016-12-31 | CN¥8.92 Billion ≈ $1.31 Billion |
+15.75% |
| 2015-12-31 | CN¥7.71 Billion ≈ $1.13 Billion |
-1.87% |
| 2014-12-31 | CN¥7.85 Billion ≈ $1.15 Billion |
+29.40% |
| 2013-12-31 | CN¥6.07 Billion ≈ $888.04 Million |
+85.06% |
| 2012-12-31 | CN¥3.28 Billion ≈ $479.87 Million |
+14.74% |
| 2011-12-31 | CN¥2.86 Billion ≈ $418.24 Million |
+40.95% |
| 2010-12-31 | CN¥2.03 Billion ≈ $296.72 Million |
+9.36% |
| 2009-12-31 | CN¥1.85 Billion ≈ $271.33 Million |
+36.82% |
| 2008-12-31 | CN¥1.36 Billion ≈ $198.31 Million |
+21.04% |
| 2007-12-31 | CN¥1.12 Billion ≈ $163.83 Million |
-27.29% |
| 2006-12-31 | CN¥1.54 Billion ≈ $225.32 Million |
+29.45% |
| 2005-12-31 | CN¥1.19 Billion ≈ $174.06 Million |
+43.94% |
| 2004-12-31 | CN¥826.42 Million ≈ $120.93 Million |
+43.54% |
| 2003-12-31 | CN¥575.74 Million ≈ $84.25 Million |
+126.94% |
| 2002-12-31 | CN¥253.70 Million ≈ $37.12 Million |
-27.14% |
| 2001-12-31 | CN¥348.19 Million ≈ $50.95 Million |
+31.82% |
| 2000-12-31 | CN¥264.15 Million ≈ $38.65 Million |
+22.69% |
| 1999-12-31 | CN¥215.29 Million ≈ $31.50 Million |
-- |
About Tasly Pharmaceutical Group Co Ltd
Tasly Pharmaceutical Group Co., Ltd, together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China. The company offers prescription drugs covering various therapeutic areas, including cardiovascular-cerebrovascular, tumor immunity, digestion and metabolism, and neuroscience; over-the-counter drugs; modern TCM; biological drugs; and chemical… Read more